Quest Diagnostics Incorporated (NYSE:DGX) Stock Holdings Lifted by Waterway Wealth Management LLC

Waterway Wealth Management LLC raised its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,955 shares of the medical research company’s stock after buying an additional 104 shares during the period. Waterway Wealth Management LLC’s holdings in Quest Diagnostics were worth $614,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of DGX. GAMMA Investing LLC increased its holdings in shares of Quest Diagnostics by 25.6% in the first quarter. GAMMA Investing LLC now owns 652 shares of the medical research company’s stock valued at $87,000 after buying an additional 133 shares in the last quarter. Mather Group LLC. acquired a new stake in shares of Quest Diagnostics in the first quarter worth $60,000. Riverview Trust Co purchased a new position in shares of Quest Diagnostics during the first quarter valued at $33,000. Franklin Street Advisors Inc. NC acquired a new position in Quest Diagnostics during the first quarter valued at $245,000. Finally, Atwater Malick LLC lifted its stake in Quest Diagnostics by 1.4% in the 1st quarter. Atwater Malick LLC now owns 54,749 shares of the medical research company’s stock worth $7,288,000 after acquiring an additional 779 shares in the last quarter. Institutional investors own 88.06% of the company’s stock.

Insider Activity at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 1,990 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, SVP Karthik Kuppusamy sold 1,990 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mark E. Delaney sold 420 shares of the firm’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the completion of the transaction, the senior vice president now owns 5,019 shares in the company, valued at $718,118.52. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by company insiders.

Quest Diagnostics Stock Down 1.5 %

Quest Diagnostics stock opened at $147.40 on Tuesday. The company has a market capitalization of $16.37 billion, a P/E ratio of 19.84, a P/E/G ratio of 2.45 and a beta of 0.89. The firm’s fifty day simple moving average is $152.60 and its 200-day simple moving average is $144.20. The company has a current ratio of 1.00, a quick ratio of 0.91 and a debt-to-equity ratio of 0.57. Quest Diagnostics Incorporated has a 1-year low of $120.87 and a 1-year high of $159.36.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.31 by $0.04. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. Quest Diagnostics’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.30 EPS. Sell-side analysts forecast that Quest Diagnostics Incorporated will post 8.89 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, October 21st. Investors of record on Friday, October 4th were paid a $0.75 dividend. The ex-dividend date was Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a yield of 2.04%. Quest Diagnostics’s payout ratio is presently 40.38%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DGX. Barclays lifted their target price on Quest Diagnostics from $144.00 to $154.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 27th. Piper Sandler upped their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a research note on Monday, July 29th. Truist Financial lifted their target price on shares of Quest Diagnostics from $158.00 to $165.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Robert W. Baird upped their price target on shares of Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, Citigroup raised Quest Diagnostics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $145.00 to $165.00 in a research report on Wednesday, July 10th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $154.92.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.